Stock Research Monitor: EDAP, AMDA, and AVGR
LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on PAVM sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Medical Appliances and Equipment space, which is engaged in the manufacture of medical instruments such as dental and surgical appliances. Companies in this category tend to offer below-average dividend yields when compared to the wider market. Under evaluation this morning are these four stocks: EDAP TMS S.A. (NASDAQ: EDAP), PAVmed Inc. (NASDAQ: PAVM), Amedica Corp. (NASDAQ: AMDA), and Avinger Inc. (NASDAQ: AVGR). All you have to do is sign up today for this free limited time offer by clicking the link below.
Shares in Vaulx-en-Velin, France-based EDAP TMS S.A. saw a decline of 1.54%, ending Monday's trading session at $3.20. The stock recorded a trading volume of 25,212 shares. The Company's shares have surged 35.02% over the last three months. The stock is trading 11.98% and 17.78% above its 50-day and 200-day moving averages, respectively. Moreover, shares of EDAP, which together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide, have a Relative Strength Index (RSI) of 55.11. Get the full research report on EDAP for free by clicking below at:
New York-based PAVmed Inc.'s stock rose 3.80%, closing the day at $1.64. A total volume of 2.21 million shares was traded, which was above their three months average volume of 650,870 shares. The Company's shares have surged 70.82% in the past month. The stock is trading 38.95% above its 50-day moving average. Additionally, shares of PAVmed, which operates as a medical device company in the US, have an RSI of 80.98.
On June 28th, 2018, research firm Maxim Group initiated a 'Buy' rating on the Company's stock, with a target price of $5 per share.
On July 11th, 2018, PAVmed announced that it has named Shaun M. O'Neil to serve as the Company's first Chief Commercial Officer. Mr. O'Neil will oversee all aspects of the domestic and international commercialization of the Company's products, including sales and marketing, clinician engagement, and professional education. He reports directly to Lishan Aklog, M.D., Chairman and CEO. Access the free research report on PAVM now by signing up at:
On Monday, shares in Salt Lake City, Utah headquartered Amedica Corp. recorded a trading volume of 160,805 shares. The stock ended the day 10.37% lower at $0.43. The Company's shares are trading below their 50-day moving average by 55.63%. Furthermore, shares of Amedica, which develops, manufactures, and commercializes a range of medical devices based on its silicon nitride technology platform in the US, Europe, and South America, have an RSI of 19.79. Are you already registered with Wall St. Equities? Do so now for free, and get the report on AMDA at:
Redwood City, California headquartered Avinger Inc.'s stock climbed 1.81%, finishing yesterday's session at $1.40 with a total trading volume of 124,987 shares. The Company's shares have advanced 16.12% in the previous three months. The stock is trading below its 50-day moving average by 12.40%. Additionally, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 35.44.
On July 10th, 2018, Avinger announced the appointment of Jaafer Golzar, MD, as its Chief Medical Officer, effective immediately. Dr. Golzar provides the Company with an extensive and impressive history of clinical leadership within the endovascular field.Aspiring Member, please take a moment to register below for your free research report on AVGR at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities